{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:18:22Z","timestamp":1761707902093},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T00:00:00Z","timestamp":1148256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1245\/aso.2006.07.011","type":"journal-article","created":{"date-parts":[[2006,5,20]],"date-time":"2006-05-20T05:48:33Z","timestamp":1148104113000},"page":"933-939","source":"Crossref","is-referenced-by-count":97,"title":["Activated Akt and Erk Expression and Survival After Surgery in Pancreatic Carcinoma"],"prefix":"10.1245","volume":"13","author":[{"given":"Krishdeep S.","family":"Chadha","sequence":"first","affiliation":[]},{"given":"Thaer","family":"Khoury","sequence":"additional","affiliation":[]},{"given":"Jihnhee","family":"Yu","sequence":"additional","affiliation":[]},{"given":"Jennifer D.","family":"Black","sequence":"additional","affiliation":[]},{"given":"John F.","family":"Gibbs","sequence":"additional","affiliation":[]},{"given":"Boris W.","family":"Kuvshinoff","sequence":"additional","affiliation":[]},{"given":"Dongfeng","family":"Tan","sequence":"additional","affiliation":[]},{"given":"Michael G.","family":"Brattain","sequence":"additional","affiliation":[]},{"given":"Milind M.","family":"Javle","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2006,5,22]]},"reference":[{"key":"10365_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1072-7515(99)00075-7","volume":"189","author":"SF Sener","year":"1999","unstructured":"Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment, survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189:1\u20137","journal-title":"J Am Coll Surg"},{"key":"10365_CR2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10\u201330","journal-title":"CA Cancer J Clin"},{"key":"10365_CR3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1245\/ASO.2003.06.015","volume":"10","author":"QD Chu","year":"2003","unstructured":"Chu QD, Khushalani N, Javle MM, Douglass HO Jr, Gibbs JF. Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas? Ann Surg Oncol 2003; 10:539\u201345","journal-title":"Ann Surg Oncol"},{"key":"10365_CR4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0022-4804(90)90133-M","volume":"49","author":"R Bleday","year":"1990","unstructured":"Bleday R, Tzanakakis GN, Schwalke MA, Wanebo HJ, Vezeridis MP. Epidermal growth factor stimulation and metastatic rate in human pancreatic carcinoma cell lines. J Surg Res 1990; 49:276\u20139","journal-title":"J Surg Res"},{"key":"10365_CR5","first-page":"425","volume":"22","author":"LE Clarke","year":"2003","unstructured":"Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR. Int J Oncol 2003; 22:425\u201330","journal-title":"Int J Oncol"},{"key":"10365_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1272\/jnms1923.59.51","volume":"59","author":"Y Yamanaka","year":"1992","unstructured":"Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi 1992; 59:51\u201361","journal-title":"Nippon Ika Daigaku Zasshi"},{"key":"10365_CR7","first-page":"1303","volume":"25","author":"X Tan","year":"2004","unstructured":"Tan X, Egami H, Ishikawa S, et al. Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer. Int J Oncol 2004; 25:1303\u20139","journal-title":"Int J Oncol"},{"key":"10365_CR8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/00006676-200407000-00061","volume":"29","author":"S Ueda","year":"2004","unstructured":"Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004; 29:e1\u20138","journal-title":"Pancreas"},{"key":"10365_CR9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00006676-200211000-00004","volume":"25","author":"J Feng","year":"2002","unstructured":"Feng J, Adsay NV, Kruger M, et al. Expression of ERRP in normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinoma. Pancreas 2002; 25:342\u20139","journal-title":"Pancreas"},{"key":"10365_CR10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14712598.5.8.1085","volume":"5","author":"B Burtness","year":"2005","unstructured":"Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005; 5:1085\u201393","journal-title":"Expert Opin Biol Ther"},{"key":"10365_CR11","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2004.12.040","volume":"22","author":"HQ Xiong","year":"2004","unstructured":"Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004; 22:2610\u20136","journal-title":"J Clin Oncol"},{"key":"10365_CR12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201\u20138","journal-title":"J Clin Oncol"},{"key":"10365_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","volume":"10","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005; 10:461\u20136","journal-title":"Oncologist"},{"key":"10365_CR14","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646\u201354","journal-title":"J Clin Oncol"},{"key":"10365_CR15","first-page":"2478","volume":"9","author":"SN Malik","year":"2003","unstructured":"Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9:2478\u201386","journal-title":"Clin Cancer Res"},{"key":"10365_CR16","first-page":"1168","volume":"8","author":"SN Malik","year":"2002","unstructured":"Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8:1168\u201371","journal-title":"Clin Cancer Res"},{"key":"10365_CR17","first-page":"135","volume":"85","author":"SN Malik","year":"2003","unstructured":"Malik SN, Bedolla RG, Hidalgo M, Brattain MG, Kreisberg JI. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples. Methods Mol Med 2003; 85:135\u201340","journal-title":"Methods Mol Med"},{"key":"10365_CR18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.0.CO;2-L","volume":"175","author":"D Jiang","year":"1998","unstructured":"Jiang D, Liang J, Humphrey LE, Yang H, Brattain MG. Expression of TGFalpha autocrine activity in human colon carcinoma CBS cells is autoregulated and independent of exogenous epidermal growth factor. J Cell Physiol 1998; 175:174\u201383","journal-title":"J Cell Physiol"},{"key":"10365_CR19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/(SICI)1096-9896(200006)191:2<154::AID-PATH603>3.0.CO;2-C","volume":"191","author":"J Luttges","year":"2000","unstructured":"Luttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Kloppel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol 2000; 191:154\u201361","journal-title":"J Pathol"},{"key":"10365_CR20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00268-003-7165-7","volume":"27","author":"HG Beger","year":"2003","unstructured":"Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003; 27:1075\u201384","journal-title":"World J Surg"},{"key":"10365_CR21","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1158\/1078-0432.CCR-04-1385","volume":"11","author":"A Shah","year":"2005","unstructured":"Shah A, Swain WA, Richardson D, et al. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11:2930\u20136","journal-title":"Clin Cancer Res"},{"key":"10365_CR22","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1038\/sj.onc.1209100","volume":"24","author":"JR Testa","year":"2005","unstructured":"Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24:7391\u20133","journal-title":"Oncogene"},{"key":"10365_CR23","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1073\/pnas.211430998","volume":"98","author":"JR Testa","year":"2001","unstructured":"Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001; 98:10983\u20135","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10365_CR24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0","volume":"79","author":"MJ Boucher","year":"2000","unstructured":"Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK\/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000; 79:355\u201369","journal-title":"J Cell Biochem"},{"key":"10365_CR25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1006\/bbrc.2001.4595","volume":"282","author":"XZ Ding","year":"2001","unstructured":"Ding XZ, Adrian TE. MEK\/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochem Biophys Res Commun 2001; 282:447\u201353","journal-title":"Biochem Biophys Res Commun"},{"key":"10365_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2005.04.095","volume":"332","author":"W Motomura","year":"2005","unstructured":"Motomura W, Tanno S, Takahashi N, et al. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem Biophys Res Commun 2005; 332:89\u201394","journal-title":"Biochem Biophys Res Commun"},{"key":"10365_CR27","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1158\/0008-5472.CAN-04-2848","volume":"65","author":"S Gysin","year":"2005","unstructured":"Gysin S, Lee SH, Dean NM, McMahon M. Pharmacologic inhibition of RAF\u2192MEK\u2192ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 2005; 65:4870\u201380","journal-title":"Cancer Res"},{"key":"10365_CR28","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-02-1441","volume":"10","author":"S Yamamoto","year":"2004","unstructured":"Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10:2846\u201350","journal-title":"Clin Cancer Res"},{"key":"10365_CR29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0360-3016(98)00179-5","volume":"42","author":"WF Regine","year":"1998","unstructured":"Regine WF, Abrams RA. Adjuvant therapy for pancreatic cancer: back to the future. Int J Radiat Oncol Biol Phys 1998; 42:59\u201363","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10365_CR30","first-page":"509","volume":"58","author":"K Okami","year":"1998","unstructured":"Okami K, Wu L, Riggins G, et al. Analysis of PTEN\/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998; 58:509\u201311","journal-title":"Cancer Res"},{"key":"10365_CR31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4161\/cc.5.1.2291","volume":"5","author":"BZ Stanger","year":"2006","unstructured":"Stanger BZ, Dor Y. Dissecting the cellular origins of pancreatic cancer. Cell Cycle 2006; 5:43\u20136","journal-title":"Cell Cycle"},{"key":"10365_CR32","first-page":"470","volume":"88","author":"DA Altomare","year":"2003","unstructured":"Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2003; 88:470\u20136","journal-title":"J Cell Biochem"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/ASO.2006.07.011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/ASO.2006.07.011\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/ASO.2006.07.011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T16:21:32Z","timestamp":1572970892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/ASO.2006.07.011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,22]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10365"],"URL":"https:\/\/doi.org\/10.1245\/aso.2006.07.011","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,22]]}}}